Andreeva E, Bobyleva P, Gornostaeva A, Buravkova L. Interaction of multipotent mesenchymal stromal and immune cells: bidirectional effects. Cytotherapy. 2017;19(10):1152–66.

CAS  PubMed  Google Scholar 

Baharlooi H, Azimi M, Salehi Z, Izad M. Mesenchymal stem cell-derived exosomes: A promising therapeutic Ace card to address autoimmune diseases. Int J Stem Cells. 2020;13(1):13–23.

CAS  PubMed  Google Scholar 

Ben-Ami E, Berrih-Aknin S, Miller A. Mesenchymal stem cells as an Immunomodulatory therapeutic strategy for autoimmune diseases. Autoimmun Rev. 2011;10(7):410–5.

CAS  PubMed  Google Scholar 

Ménard C, Tarte K. Immunoregulatory properties of clinical grade mesenchymal stromal cells: evidence, uncertainties, and clinical application. Stem Cell Res Ther. 2013;4(3):64.

PubMed  PubMed Central  Google Scholar 

Andrzejewska A, Lukomska B, Janowski M. Concise review: mesenchymal stem cells: from roots to boost. Stem Cells. 2019;37(7):855–64.

PubMed  Google Scholar 

Benvenuto F, Voci A, Carminati E, Gualandi F, Mancardi G, Uccelli A, et al. Human mesenchymal stem cells target adhesion molecules and receptors involved in T cell extravasation. Stem Cell Res Ther. 2015;6:245.

PubMed  PubMed Central  Google Scholar 

Negi N, Griffin MD. Effects of mesenchymal stromal cells on regulatory T cells: current Understanding and clinical relevance. Stem Cells. 2020;38(5):596–605.

PubMed  Google Scholar 

Djouad F, Charbonnier L-M, Bouffi C, Louis-Plence P, Bony C, Apparailly F, et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells. 2007;25(8):2025–32.

CAS  PubMed  Google Scholar 

Hof-Nahor I, Leshansky L, Shivtiel S, Eldor L, Aberdam D, Itskovitz-eldor J, et al. Human mesenchymal stem cells shift CD8 + T cells towards a suppressive phenotype by inducing tolerogenic monocytes. J Cell Sci. 2012;125(Pt 19):4640–50.

CAS  PubMed  Google Scholar 

Melief SM, Zwaginga JJ, Fibbe WE, Roelofs H. Adipose Tissue-Derived multipotent stromal cells have a higher Immunomodulatory capacity than their bone Marrow-Derived counterparts. Stem Cells Transl Med. 2013;2(6):455463.

Google Scholar 

Crippa S, Conti A, Vavassori V, Ferrari S, Beretta S, Rivis S, et al. Mesenchymal stromal cells improve the transplantation outcome of CRISPR-Cas9 gene-edited human HSPCs. Mol Ther. 2023;31(1):230–48.

CAS  PubMed  Google Scholar 

Habiba UE, Khan N, Greene DL, Ahmad K, Shamim S, Umer A. Meta-analysis shows that mesenchymal stem cell therapy can be a possible treatment for diabetes. Front Endocrinol. 2024;15:1380443.

Google Scholar 

Kadri N, Amu S, Iacobaeus E, Boberg E, Le Blanc K. Current perspectives on mesenchymal stromal cell therapy for graft versus host disease. Cell Mol Immunol. 2023;20(6):613–25.

CAS  PubMed  PubMed Central  Google Scholar 

Kotani T, Saito T, Suzuka T, Matsuda S. Adipose-derived mesenchymal stem cell therapy for connective tissue diseases and complications. Inflamm Regeneration. 2024;44(1):35.

Google Scholar 

Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: an update. Cell Transpl. 2016;25(5):829–48.

Google Scholar 

Leyendecker A, Pinheiro CCG, Amano MT, Bueno DF. The use of human mesenchymal stem cells as therapeutic agents for the in vivo treatment of immune-related diseases: A systematic review. Front Immunol. 2018;9:2056.

PubMed  Google Scholar 

Galipeau J, Krampera M, Barrett J, Dazzi F, Deans RJ, DeBruijn J, et al. International society for cellular therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy. 2016;18(2):151–9.

CAS  PubMed  Google Scholar 

de Wolf C, van de Bovenkamp M, Hoefnagel M. Regulatory perspective on in vitro potency assays for human mesenchymal stromal cells used in immunotherapy. Cytotherapy. 2017;19(7):784–97.

PubMed  Google Scholar 

Chinnadurai R, Viswanathan S, Moll G. Editorial: Next generation MSC therapy manufacturing, potency and mechanism of action analysis. Front Immunol. 2023;14:1192636.

CAS  PubMed  PubMed Central  Google Scholar 

Galipeau J. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824–33.

CAS  PubMed  PubMed Central  Google Scholar 

Guess AJ, Daneault B, Wang R, Bradbury H, La Perle KMD, Fitch J, et al. Safety profile of good manufacturing practice manufactured interferon γ-Primed mesenchymal stem/stromal cells for clinical trials. Stem Cells Transl Med. 2017;6(10):1868–79.

CAS  PubMed  PubMed Central  Google Scholar 

Krampera M, Le Blanc K. Mesenchymal stromal cells: putative microenvironmental modulators become cell therapy. Cell Stem Cell. 2021;28(10):1708–25.

CAS  PubMed  Google Scholar 

Daumas A, Magalon J, Jouve E, Casanova D, Philandrianos C, Abellan Lopez M, et al. Adipose tissue-derived stromal vascular fraction for treating hands of patients with systemic sclerosis: a multicentre randomized trial autologous AD-SVF versus placebo in systemic sclerosis. Rheumatology. 2022;61(5):1936–47.

CAS  PubMed  Google Scholar 

Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, et al. Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with crohn’s disease. Gastroenterology. 2018;154(5):1334–e13424.

PubMed  Google Scholar 

Chinnadurai R, Copland IB, Garcia MA, Petersen CT, Lewis CN, Waller EK, et al. Cryopreserved mesenchymal stromal cells are susceptible to T-Cell mediated apoptosis which is partly rescued by IFNγ licensing. Stem Cells. 2016;34(9):2429–42.

CAS  PubMed  Google Scholar 

Giri J, Galipeau J. Mesenchymal stromal cell therapeutic potency is dependent upon viability, route of delivery, and immune match. Blood Adv. 2020;4(9):1987–97.

CAS  PubMed  PubMed Central  Google Scholar 

Mebarki M, Iglicki N, Marigny C, Abadie C, Nicolet C, Churlaud G, et al. Development of a human umbilical cord-derived mesenchymal stromal cell-based advanced therapy medicinal product to treat immune and/or inflammatory diseases. Stem Cell Res Ther. 2021;12(1):571.

CAS  PubMed  PubMed Central  Google Scholar 

Kim DS, Jang IK, Lee MW, Ko YJ, Lee DH, Lee JW, et al. Enhanced immunosuppressive properties of human mesenchymal stem cells primed by Interferon-γ. EBioMedicine. 2018;28:261–73.

PubMed  PubMed Central  Google Scholar 

de Witte SFH, Merino AM, Franquesa M, Strini T, Van Zoggel JAA, Korevaar SS, et al. Cytokine treatment optimises the immunotherapeutic effects of umbilical cord-derived MSC for treatment of inflammatory liver disease. Stem Cell Res Ther. 2017;8(1):140.

PubMed  PubMed Central  Google Scholar 

Chinnadurai R, Rajan D, Qayed M, Arafat D, Garcia M, Liu Y, et al. Potency analysis of mesenchymal stromal cells using a combinatorial assay matrix approach. Cell Rep. 2018;22(9):2504–17.

CAS  PubMed  PubMed Central  Google Scholar 

Guan Q, Ezzati P, Spicer V, Krokhin O, Wall D, Wilkins JA. Interferon γ induced compositional changes in human bone marrow derived mesenchymal stem/stromal cells. Clin Proteom 2017:14(26).

García-Guerrero CA, Fuentes P, Araya MJ, Djouad F, Luz-Crawford P, Vega-Letter AM, et al. How to enhance MSCs therapeutic properties? An insight on potentiation methods. Stem Cell Res Ther. 2024;15(1):331.

PubMed  PubMed Central  Google Scholar 

Herger N, Heggli I, Mengis T, Devan J, Arpesella L, Brunner F, et al. Impacts of priming on distinct immunosuppressive mechanisms of mesenchymal stromal cells under translationally relevant conditions. Stem Cell Res Ther. 2024;15(1):65.

CAS  PubMed  PubMed Central  Google Scholar 

Sudres M, Maurer M, Robinet M, Bismuth J, Truffault F, Girard D, et al. Preconditioned mesenchymal stem cells treat myasthenia Gravis in a humanized preclinical model. JCI Insight. 2017;2(7):e89665.

PubMed  PubMed Central  Google Scholar 

Griffin MD, Ryan AE, Alagesan S, Lohan P, Treacy O, Ritter T. Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so Far. Immunol Cell Biol. 2013;91(1):40–51.

CAS  PubMed  Google Scholar 

Sivanathan KN, Gronthos S, Rojas-Canales D, Thierry B, Coates PT. Interferon-gamma modification of mesenchymal stem cells: implications of autologous and allogeneic mesenchymal stem cell therapy in allotransplantation. Stem Cell Rev Rep. 2014;10(3):351–75.

CAS  PubMed  Google Scholar 

Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJ. G M. Myasthenia gravis. Nature reviews. Disease Primers. 2019;5(1):30.

PubMed  Google Scholar 

Berrih-Aknin S, Le Panse. Myasthenia gravis: A comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun. 2014;52:90–100.

CAS  PubMed  Google Scholar 

Huijbers MG, Marx A, Plomp JJ, Le Panse R, Phillips WD. Advances in the Understanding of disease mechanisms of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022;21(2):163–75.